Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/16881
Title: | Model based estimates of long-term persistence of inactivated hepatitis: A vaccine-induced antibodies in adults | Authors: | HENS, Niel HABTEAB GHEBRETINSAE, Aklilu Hardt, Karin Van Damme, Pierre Van Herck, Koen |
Issue Date: | 2014 | Source: | VACCINE, 32 (13), p. 1507-1513 | Abstract: | Background: In this paper, we review the results of existing statistical models of the long-term persistence of hepatitis A vaccine-induced antibodies in light of recently available immunogenicity data from 2 clinical trials (up to 17 years of follow-up). Methods: Healthy adult volunteers monitored annually for 17 years after the administration of the first vaccine dose in 2 double-blind, randomized clinical trials were included in this analysis. Vaccination in these studies was administered according to a 2-dose vaccination schedule: 0, 12 months in study A and 0, 6 months in study B (NCT00289757/NCT00291876). Antibodies were measured using an in-house ELISA during the first 11 years of follow-up; a commercially available ELISA was then used up to Year17 of follow-up. Long-term antibody persistence from studies A and B was estimated using statistical models for longitudinal data. Data from studies A and B were modeled separately. Results: A total of 173 participants in study A and 108 participants in study B were included in the analysis. A linear mixed model with 2 change points allowed all available results to be accounted for. Predictions based on this model indicated that 98% (95%CI: 94–100%) of participants in study A and 97% (95%CI:94–100%) of participants in study B will remain seropositive 25 years after receiving the first vaccine dose. Other models using part of the data provided consistent results: ≥95% of the participants was projected to remain seropositive for ≥25 years. Conclusion: This analysis, using previously used and newly selected model structures, was consistent with former estimates of seropositivity rates ≥95% for at least 25 years. | Keywords: | vaccine trials; immunogenicity assay; longitudinal data analysis; changepoint model; long term follow-up | Document URI: | http://hdl.handle.net/1942/16881 | ISSN: | 0264-410X | e-ISSN: | 1873-2518 | DOI: | 10.1016/j.vaccine.2013.10.088 | ISI #: | 000335617600014 | Rights: | © 2014 Elsevier Ltd. All rights reserved. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2015 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Hens et al. Vaccine 2014.pdf Restricted Access | 1.06 MB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
37
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
47
checked on Sep 12, 2024
Page view(s)
92
checked on Sep 7, 2022
Download(s)
80
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.